Baricitinib
The spectrum of systemic treatment options in AE has recently expanded
by approval of baricitinib, an oral JAK inhibitor. The small molecule
has been proved efficacy and safety in several RCTs with an improvement
of itch, patient-oriented eczema measure and DLQI [127].